1. Home
  2. FGMC vs ELTX Comparison

FGMC vs ELTX Comparison

Compare FGMC & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGMC
  • ELTX
  • Stock Information
  • Founded
  • FGMC 2023
  • ELTX 2011
  • Country
  • FGMC United States
  • ELTX United States
  • Employees
  • FGMC N/A
  • ELTX N/A
  • Industry
  • FGMC
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FGMC
  • ELTX Health Care
  • Exchange
  • FGMC NYSE
  • ELTX Nasdaq
  • Market Cap
  • FGMC 101.8M
  • ELTX 121.7M
  • IPO Year
  • FGMC 2025
  • ELTX N/A
  • Fundamental
  • Price
  • FGMC $9.85
  • ELTX $8.09
  • Analyst Decision
  • FGMC
  • ELTX Strong Buy
  • Analyst Count
  • FGMC 0
  • ELTX 2
  • Target Price
  • FGMC N/A
  • ELTX $9.50
  • AVG Volume (30 Days)
  • FGMC 21.6K
  • ELTX 48.3K
  • Earning Date
  • FGMC 01-01-0001
  • ELTX 08-12-2025
  • Dividend Yield
  • FGMC N/A
  • ELTX N/A
  • EPS Growth
  • FGMC N/A
  • ELTX N/A
  • EPS
  • FGMC 0.08
  • ELTX N/A
  • Revenue
  • FGMC N/A
  • ELTX N/A
  • Revenue This Year
  • FGMC N/A
  • ELTX N/A
  • Revenue Next Year
  • FGMC N/A
  • ELTX N/A
  • P/E Ratio
  • FGMC $573.47
  • ELTX N/A
  • Revenue Growth
  • FGMC N/A
  • ELTX N/A
  • 52 Week Low
  • FGMC $9.53
  • ELTX $3.70
  • 52 Week High
  • FGMC $9.90
  • ELTX $9.99
  • Technical
  • Relative Strength Index (RSI)
  • FGMC N/A
  • ELTX 62.14
  • Support Level
  • FGMC N/A
  • ELTX $7.76
  • Resistance Level
  • FGMC N/A
  • ELTX $8.94
  • Average True Range (ATR)
  • FGMC 0.00
  • ELTX 0.37
  • MACD
  • FGMC 0.00
  • ELTX -0.03
  • Stochastic Oscillator
  • FGMC 0.00
  • ELTX 51.09

About FGMC FG MERGER II CORP

FG Merger II Corp is a blank check company, incorporated for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (Business Combination).

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: